For patients at high risk of cardiovascular events, PCSK9 inhibitors represent a critical advancement— especially when statins alone fail. But commercial success is challenged by real-world issues: high abandonment rates, low refill persistence, and costly drop-offs.
A leading pharmaceutical brand faced exactly this challenge. They turned to MedAdvisor Solutions to address one pivotal question: How can we drive measurable adherence in a complex, chronic therapy space with precisely targeted engagement?
For the full case study, click the "Download Now" button below.